360
Participants
Start Date
June 14, 2024
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2028
SG301 Injection
Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
SG301 placebo
Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
pomalidomide
Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
dexamethasone
Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
RECRUITING
Beijing Chaoyang Hospital of Capital Medical University, Beijing
RECRUITING
The First Affiliated Hospital Of Soochow University, Suzhou
RECRUITING
Tianjin Cancer University Airport Hospital, Tianjin
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
RECRUITING
The Second Affiliated Hospital Zhejiang University School Of Medicine, Hangzhou
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
First Affiliated Hospital of Henan University of Science and Technology, Luoyang
NOT_YET_RECRUITING
Guangzhou First People's Hospital, Guangzhou
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital), Xi’an
RECRUITING
Shanxi Provincial Hospital, Taiyuan
Hangzhou Sumgen Biotech Co., Ltd.
INDUSTRY